4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of 0.00% and +142.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?